• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    7/29/25 7:05:36 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    8-K
    False0001520262Alkermes plc.00015202622025-07-292025-07-29

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): July 29, 2025

    ALKERMES PUBLIC LIMITED COMPANY

    (Exact name of registrant as specified in its charter)

     

    Ireland

     

    001-35299

     

    98-1007018

    (State or other jurisdiction

     

    (Commission

     

    (IRS Employer

    of incorporation)

     

    File Number)

     

    Identification No.)

     

     

     

     

     

     

    Connaught House, 1 Burlington Road

    Dublin 4, Ireland D04 C5Y6

    (Address of principal executive offices)

     

    Registrant's telephone number, including area code: + 353-1-772-8000

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Ordinary shares, $0.01 par value

     

    ALKS

     

    Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

     

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

     

    On July 29, 2025, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2025. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on July 29, 2025 discussing such financial results are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

    99.1

     

    Press release issued by Alkermes plc on July 29, 2025 announcing financial results for the three and six months ended June 30, 2025.

    99.2

     

    Investor presentation to be displayed by Alkermes plc on July 29, 2025.

    104

     

    Cover page interactive data file (embedded within the Inline XBRL document).

     

    2


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    ALKERMES PLC

     

     

    Date: July 29, 2025

    By:

     

    /s/ Blair C. Jackson

     

     

     

    Blair C. Jackson

     

     

     

    Executive Vice President, Chief Operating Officer (Interim Principal Financial Officer)

     

    3


    Get the next $ALKS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    More analyst ratings

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:39:56 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:37:23 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I covered exercise/tax liability with 1,924 units of Ordinary Shares and converted options into 8,013 units of Ordinary Shares, increasing direct ownership by 42% to 20,505 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/2/25 4:34:11 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    SEC Filings

    See more
    • SEC Form S-8 filed by Alkermes plc

      S-8 - Alkermes plc. (0001520262) (Filer)

      7/29/25 4:09:29 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Alkermes plc

      10-Q - Alkermes plc. (0001520262) (Filer)

      7/29/25 9:16:10 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alkermes plc. (0001520262) (Filer)

      7/29/25 7:05:36 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alkermes plc Reports Second Quarter 2025 Financial Results

      —    Second Quarter Revenues of $390.7 Million — —    GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — —    Company Reiterates 2025 Financial Expectations — —    Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive

      7/29/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

      – Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN, July 21, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the randomized double-bli

      7/21/25 6:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Report Second Quarter Financial Results on July 29, 2025

      DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plcAlkermes plc is a global biopharmaceutical

      7/15/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Alkermes Plc with a new price target

      Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00

      7/15/25 8:39:38 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Plc upgraded by UBS with a new price target

      UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00

      6/17/25 7:46:56 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Alkermes Plc with a new price target

      Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00

      5/28/25 8:55:31 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Financials

    Live finance-specific insights

    See more
    • Alkermes plc Reports Second Quarter 2025 Financial Results

      —    Second Quarter Revenues of $390.7 Million — —    GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — —    Company Reiterates 2025 Financial Expectations — —    Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive

      7/29/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Report Second Quarter Financial Results on July 29, 2025

      DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plcAlkermes plc is a global biopharmaceutical

      7/15/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes plc Reports First Quarter 2025 Financial Results

      —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev

      5/1/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

      DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

      3/7/24 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/1/23 6:16:00 PM ET
      $ALK
      $ALKS
      $AWI
      $BLDR
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

      —  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.  "Dr. Loew's deep knowledge of the oncology fi

      6/1/23 4:01:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alkermes plc

      SC 13G - Alkermes plc. (0001520262) (Subject)

      11/14/24 1:22:34 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/12/24 1:28:21 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/8/24 10:46:38 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care